- Home
- RLAY vs SION Comparison
RLAY vs SION Comparison
Compare RLAY & SION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- SION
- Stock Information
- Founded
- RLAY 2015
- SION 2019
- Country
- RLAY United States
- SION United States
- Employees
- RLAY N/A
- SION N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- SION
- Sector
- RLAY Health Care
- SION
- Exchange
- RLAY Nasdaq
- SION NYSE
- Market Cap
- RLAY 490.3M
- SION 564.4M
- IPO Year
- RLAY 2020
- SION 2025
- Fundamental
- Price
- RLAY $3.18
- SION $14.49
- Analyst Decision
- RLAY Strong Buy
- SION Strong Buy
- Analyst Count
- RLAY 11
- SION 1
- Target Price
- RLAY $18.40
- SION $32.00
- AVG Volume (30 Days)
- RLAY 1.5M
- SION 124.0K
- Earning Date
- RLAY 08-05-2025
- SION 05-12-2025
- Dividend Yield
- RLAY N/A
- SION N/A
- EPS Growth
- RLAY N/A
- SION N/A
- EPS
- RLAY N/A
- SION N/A
- Revenue
- RLAY $7,679,000.00
- SION N/A
- Revenue This Year
- RLAY $14.31
- SION N/A
- Revenue Next Year
- RLAY N/A
- SION N/A
- P/E Ratio
- RLAY N/A
- SION N/A
- Revenue Growth
- RLAY N/A
- SION N/A
- 52 Week Low
- RLAY $1.78
- SION $7.26
- 52 Week High
- RLAY $10.72
- SION $25.19
- Technical
- Relative Strength Index (RSI)
- RLAY 55.48
- SION N/A
- Support Level
- RLAY $2.98
- SION N/A
- Resistance Level
- RLAY $3.48
- SION N/A
- Average True Range (ATR)
- RLAY 0.25
- SION 0.00
- MACD
- RLAY -0.00
- SION 0.00
- Stochastic Oscillator
- RLAY 58.45
- SION 0.00
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About SION SIONNA THERAPEUTICS INC
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.